Literature DB >> 20452678

Antipsychotic medication and social cue recognition in chronic schizophrenia.

David Leland Roberts1, David Lewis Penn, Patrick Corrigan, Ilya Lipkovich, Bruce Kinon, Ryan Andrew Black.   

Abstract

Social cognition has received increased attention in schizophrenia research because it is associated with functional outcomes. Psychosocial interventions are being developed to enhance social cognition, however less attention has been paid to the association between antipsychotic medication use and social cognition. This study evaluated whether individuals treated with olanzapine (n=117) or quetiapine (n=106) achieved improvements in social cognition. Participants were drawn from a larger 6-month, multi-site, randomized, double-blind clinical trial. Social cognition was assessed using signal detection analysis of performance on the Social Cue Recognition Test. Social functioning was measured with an interpersonal functioning index and a broader quality of life measure. Results revealed that participants in both medication groups improved significantly but modestly on three out of four social cognition subscales. The small observed effect in this trial is generally consistent with previous studies, and supports the need for ongoing research into the biological mechanisms of social cognitive dysfunction in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20452678     DOI: 10.1016/j.psychres.2010.04.006

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  7 in total

1.  Reversal of social deficits by subchronic oxytocin in two autism mouse models.

Authors:  Brian L Teng; Viktoriya D Nikolova; Natallia V Riddick; Kara L Agster; James J Crowley; Lorinda K Baker; Beverly H Koller; Cort A Pedersen; Michael B Jarstfer; Sheryl S Moy
Journal:  Neuropharmacology       Date:  2015-12-31       Impact factor: 5.250

2.  Improving social cognition in schizophrenia: a pilot intervention combining computerized social cognition training with cognitive remediation.

Authors:  Jean-Pierre Lindenmayer; Susan R McGurk; Anzalee Khan; Saurabh Kaushik; Amod Thanju; Lisa Hoffman; Gladys Valdez; Deborah Wance; Edith Herrmann
Journal:  Schizophr Bull       Date:  2012-11-03       Impact factor: 9.306

Review 3.  Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review.

Authors:  Craig Karson; Ruth A Duffy; Anna Eramo; Anna-Greta Nylander; Steve J Offord
Journal:  Neuropsychiatr Dis Treat       Date:  2016-01-06       Impact factor: 2.570

4.  Risperidone improves interpersonal perception and executive function in patients with schizophrenia.

Authors:  Zhenhe Zhou; Yuanyuan Zhu; Jun Wang; Hongmei Zhu
Journal:  Neuropsychiatr Dis Treat       Date:  2016-12-28       Impact factor: 2.570

Review 5.  The Importance of Social Cognition in Improving Functional Outcomes in Schizophrenia.

Authors:  Afzal Javed; Asha Charles
Journal:  Front Psychiatry       Date:  2018-04-24       Impact factor: 4.157

6.  A systematic review of the effects of psychiatric medications on social cognition.

Authors:  Zoë Haime; Andrew J Watson; Nadia Crellin; Louise Marston; Eileen Joyce; Joanna Moncrieff
Journal:  BMC Psychiatry       Date:  2021-11-29       Impact factor: 3.630

Review 7.  Can antipsychotics improve social cognition in patients with schizophrenia?

Authors:  Katarzyna Kucharska-Pietura; Ann Mortimer
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.